ACE2, angiotensin-(1-7) and Mas receptor axis in inflammation and fibrosis

British Journal of Pharmacology

Volumn 169, Issue 3, 2013, Pages 477-492

  Simoes E Silva A C ^a   Silveira, K D ^a   Ferreira, A J ^a   Teixeira, M M ^a  

^a FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

Author keywords

angiotensin (1 7); fibrosis; inflammation; Mas receptor; renal diseases

Indexed keywords

ANGIOTENSIN 2 RECEPTOR; ANGIOTENSIN RECEPTOR ANTAGONIST; ANGIOTENSIN[1-7]; CHEMOKINE; CYTOKINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENZYME INHIBITOR; G PROTEIN COUPLED RECEPTOR; HYDRALAZINE; MAS RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE 3; MLN 4760; N ETHYLCARBAMOYL 3 [4 (5 FORMYL 4 METHOXY 2 PHENYL 1 IMIDAZOLYLMETHYL)PHENYL] 5 ISOBUTYL 2 THIOPHENESULFONAMIDE; NITRIC OXIDE SYNTHASE; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG;

ANTIDIURESIS; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; CELL PROLIFERATION; CHRONIC INFLAMMATION; DRUG BLOOD LEVEL; DRUG RECEPTOR BINDING; DRUG URINE LEVEL; FIBROGENESIS; HUMAN; IMMUNOGLOBULIN A NEPHROPATHY; INTRACELLULAR SIGNALING; KIDNEY DISEASE; KIDNEY FIBROSIS; LEUKOCYTE ACTIVATION; NEPHRITIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN SYNTHESIS INHIBITION; RECEPTOR UPREGULATION; RENAL PROTECTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RENOVASCULAR HYPERTENSION; REVIEW; VASODILATATION;

ANGIOTENSIN I; ANIMALS; CELL PROLIFERATION; FIBROSIS; HUMANS; KIDNEY; LEUKOCYTES; MODELS, BIOLOGICAL; NEPHRITIS; PEPTIDE FRAGMENTS; PEPTIDYL-DIPEPTIDASE A; PROTO-ONCOGENE PROTEINS; RECEPTORS, G-PROTEIN-COUPLED; SIGNAL TRANSDUCTION;

EID: 84877823830     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/bph.12159     Document Type: Review

References (177)

1. Agarwal D, Elks CM, Reed SD, Mariappan N, Majid DS, Francis J, (2012). Chronic exercise preserves renal structure and hemodynamics in spontaneously hypertensive rats. Antioxid Redox Signal 16: 139-152.
2. Allred AJ, Chappell MC, Ferrario CM, Diz DI, (2000). Differential actions of renal ischemic injury on the intrarenal angiotensin system. Am J Physiol Renal Physiol 279: F636-F645.
3. Alvarez A, Piqueras L, Bello R, Canet A, Moreno L, Kubes P, et al. (2001). Angiotensin II is involved in nitric oxide synthase and cyclo-oxygenase inhibition-induced leukocyte-endothelial cell interactions in vivo. Br J Pharmacol 132: 677-684.
4. Annes JP, Munger JS, Rifkin DB, (2003). Making sense of latent TGFbeta activation. J Cell Sci 116 (Pt 2): 217-224.
5. Azizi M, Menard J, (2004). Combined blockade of the renin-angiotensin system with angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor antagonists. Circulation 109: 2492-2499.
6. Baracho NC, Simoes-e-Silva AC, Khosla MC, Santos RA, (1998). Effect of selective angiotensin antagonists on the antidiuresis produced by angiotensin-(1-7) in water-loaded rats. Braz J Med Biol Res 31: 1221-1227.
7. Barroso LC, Silveira KD, Lima CX, Borges V, Bader M, Rachid M, et al. (2012). Renoprotective effects of AVE0991, a Nonpeptide Mas receptor agonist, in experimental acute renal injury. Int J Hypertens 2012: 808726.
8. Benicky J, Sanchez-Lemus E, Pavel J, Saavedra JM, (2009). Anti-inflammatory effects of angiotensin receptor blockers in the brain and the periphery. Cell Mol Neurobiol 29: 781-792.
9. Benter IF, Diz DI, Ferrario CM, (1993). Cardiovascular actions of Angiotensin-(1-7). Peptides 14: 679-684.
10. Benter IF, Ferrario CM, Morris M, Diz DI, (1995). Antihypertensive actions of Angiotensin-(1-7) in spontaneous hypertensive rats. Am J Physiol Heart Circ Physiol 269: H313-H319.
11. Benter IF, Yousif MH, Cojocel C, Al-Maghrebi M, Diz DI, (2007). Angiotensin-(1-7) prevents diabetes-induced cardiovascular dysfunction. Am J Physiol Heart Circ Physiol 292: H666-H672.
12. Benter IF, Yousif MH, Dhaunsi GS, Kaur J, Chappell MC, Diz DI, (2008). Angiotensin-(1-7) prevents activation of NADPH oxidase and renal vascular dysfunction in diabetic hypertensive rats. Am J Nephrol 28: 25-33.
13. Botelho-Santos GA, Sampaio WO, Reudelhuber TL, Bader M, Campagnole-Santos MJ, Souza dos Santos RA, (2007). Expression of an angiotensin-(1-7)-producing fusion protein in rats induced marked changes in regional vascular resistance. Am J Physiol Heart Circ Physiol 292: H2485-H2490.
14. Britto RR, Santos RA, Fagundes-Moura CR, Khosla MC, Campagnole-Santos MJ, (1997). Role of angiotensin-(1-7) in the modulation of the baroreflex in renovascular hypertensive rats. Hypertension 30 (3 Pt 2): 549-556.
15. Burgelova M, Kramer HJ, Teplan V, Velickova G, Vitko S, Heller J, et al. (2002). Intrarenal infusion of angiotensin-(1-7) modulates renal functional responses to exogenous angiotensin II in the rat. Kidney Blood Press Res 25: 202-210.
16. Campagnole-Santos MJ, Diz DI, Santos RA, Khosla MC, Brosnihan KB, Ferrario CM, (1989). Cardiovascular effects of angiotensin-(1-7) injected into the dorsal medulla of rats. Am J Physiol 257 (1 Pt 2): H324-H329.
17. Campbell SE, Katwa LC, (1997). Angiotensin II stimulated expression of transforming growth factor-beta1 in cardiac fibroblasts and myofibroblasts. J Mol Cell Cardiol 29: 1947-1958.
18. Capettini LS, Montecucco F, Mach F, Stergiopulos N, Santos RA, da Silva RF, (2012). Role of renin-angiotensin system in inflammation, immunity and aging. Curr Pharm Des 18: 963-970.
19. Chappell MC, Diz DI, Yunis C, Ferrario CM, (1998a). Differential actions of angiotensin-(1-7) in the kidney. Kidney Int Suppl 68: S3-S6.
20. Chappell MC, Pirro NT, Sykes A, Ferrario CM, (1998b). Metabolism of angiotensin-(1-7) by angiotensin-converting enzyme. Hypertension 31 (1 Pt 2): 362-367.
21. Chappell MC, Allred AJ, Ferrario CM, (2001). Pathways of angiotensin-(1-7) metabolism in the kidney. Nephrol Dial Transplant 16 (Suppl. 1): 22-26.
22. Chappell MC, Modrall JG, Diz DI, Ferrario CM, (2004). Novel aspects of the renal renin-angiotensin system: angiotensin-(1-7), ACE2 and blood pressure regulation. Contrib Nephrol 143: 77-89.
23. Company C, Piqueras L, Naim Abu Nabah Y, Escudero P, Blanes JI, Jose PJ, et al. (2011). Contributions of ACE and mast cell chymase to endogenous angiotensin II generation and leucocyte recruitment in vivo. Cardiovasc Res 92: 48-56.
24. Crackower MA, Sarao R, Oudit GY, Yagil C, Kozieradzki I, Scanga SE, et al. (2002). Angiotensin-converting enzyme 2 is an essential regulator of heart function. Nature 417: 822-828.
25. Davie AP, McMurray JJ, (1999). Effect of angiotensin-(1-7) and bradykinin in patients with heart failure treated with an ACE inhibitor. Hypertension 34: 457-460.
26. DelliPizzi AM, Hilchey SD, Bell-Quilley CP, (1994). Natriuretic action of angiotensin(1-7). Br J Pharmacol 111: 1-3.
27. Der Sarkissian S, Grobe JL, Yuan L, Narielwala DR, Walter GA, Katovich MJ, et al. (2008). Cardiac overexpression of angiotensin converting enzyme 2 protects the heart from ischemia-induced pathophysiology. Hypertension 51: 712-718.
28. Dilauro M, Zimpelmann J, Robertson SJ, Genest D, Burns KD, (2010). Effect of ACE2 and angiotensin-(1-7) in a mouse model of early chronic kidney disease. Am J Physiol Renal Physiol 298: F1523-F1532.
29. Donoghue M, Hsieh F, Baronas E, Godbout K, Gosselin M, Stagliano N, et al. (2000). A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9. Circ Res 87: E1-E9.
30. El-Hashim AZ, Renno WM, Raghupathy R, Abduo HT, Akhtar S, Benter IF, (2012). Angiotensin-(1-7) inhibits allergic inflammation, via the MAS1 receptor, through suppression of ERK1/2- and NF-kappaB-dependent pathways. Br J Pharmacol 166: 1964-1976.
31. Esteban V, Heringer-Walther S, Sterner-Kock A, de Bruin R, van den Engel S, Wang Y, et al. (2009). Angiotensin-(1-7) and the g protein-coupled receptor MAS are key players in renal inflammation. Plos ONE 4: e5406.
32. Ferrario CM, (1990). The renin-angiotensin system: importance in physiology and pathology. J Cardiovasc Pharmacol 15 (Suppl. 3): S1-S5.
33. Ferrario CM, (2011). ACE2: more of Ang-(1-7) or less Ang II? Curr Opin Nephrol Hypertens 20: 1-6.
34. Ferrario CM, Martell N, Yunis C, Flack JM, Chappell MC, Brosnihan KB, et al. (1998). Characterization of angiotensin-(1-7) in the urine of normal and essential hypertensive subjects. Am J Hypertens 11: 137-146.
35. Ferrario CM, Smith RD, Brosnihan B, Chappell MC, Campese VM, Vesterqvist O, et al. (2002). Effects of omapatrilat on the renin-angiotensin system in salt-sensitive hypertension. Am J Hypertens 15: 557-564.
36. Ferrario CM, Jessup J, Gallagher PE, Averill DB, Brosnihan KB, Ann Tallant E, et al. (2005). Effects of renin-angiotensin system blockade on renal angiotensin-(1-7) forming enzymes and receptors. Kidney Int 68: 2189-2196.
37. Ferreira AJ, Santos RA, (2005). Cardiovascular actions of angiotensin-(1-7). Braz J Med Biol Res 38: 499-507.
38. Ferreira AJ, Pinheiro SV, Castro CH, Silva GA, Silva AC, Almeida AP, et al. (2006). Renal function in transgenic rats expressing an angiotensin-(1-7)- producing fusion protein. Regul Pept 137: 128-133.
39. Ferreira AJ, Shenoy V, Yamazato Y, Sriramula S, Francis J, Yuan L, et al. (2009). Evidence for angiotensin-converting enzyme 2 as a therapeutic target for the prevention of pulmonary hypertension. Am J Respir Crit Care Med 179: 1048-1054.
40. Ferreira AJ, Castro CH, Guatimosim S, Almeida PW, Gomes ER, Dias-Peixoto MF, et al. (2010). Attenuation of isoproterenol-induced cardiac fibrosis in transgenic rats harboring an angiotensin-(1-7)-producing fusion protein in the heart. Ther Adv Cardiovasc Dis 4: 83-96.
41. Ferreira AJ, Shenoy V, Qi Y, Fraga-Silva RA, Santos RA, Katovich MJ, et al. (2011). Angiotensin-converting enzyme 2 activation protects against hypertension-induced cardiac fibrosis involving extracellular signal-regulated kinases. Exp Physiol 96: 287-294.
42. Ferreira AJ, Murca TM, Fraga-Silva RA, Castro CH, Raizada MK, Santos RA, (2012). New cardiovascular and pulmonary therapeutic strategies based on the Angiotensin-converting enzyme 2/angiotensin-(1-7)/mas receptor axis. Int J Hypertens 2012: 147825.
43. Gallagher PE, Tallant EA, (2004). Inhibition of human lung cancer cell growth by angiotensin-(1-7). Carcinogenesis 25: 2045-2052.
44. Garcia NH, Garvin JL, (1994). Angiotensin 1-7 has a biphasic effect on fluid absorption in the proximal straight tubule. J Am Soc Nephrol 5: 1133-1138.
45. Gava E, Samad-Zadeh A, Zimpelmann J, Bahramifarid N, Kitten GT, Santos RA, et al. (2009). Angiotensin-(1-7) activates a tyrosine phosphatase and inhibits glucose-induced signalling in proximal tubular cells. Nephrol Dial Transplant 24: 1766-1773.
46. Gava E, de Castro CH, Ferreira AJ, Colleta H, Melo MB, Alenina N, et al. (2012). Angiotensin-(1-7) receptor Mas is an essential modulator of extracellular matrix protein expression in the heart. Regul Pept 175: 30-42.
47. Gerc V, Buksa M, (2010). Advantages of renin-angiotensin system blockade in the treatment of cardiovascular diseases. Med Arh 64: 295-299.
48. Giani JF, Munoz MC, Pons RA, Cao G, Toblli JE, Turyn D, et al. (2011). Angiotensin-(1-7) reduces proteinuria and diminishes structural damage in renal tissue of stroke-prone spontaneously hypertensive rats. Am J Physiol Renal Physiol 300: F272-F282.
49. Giani JF, Burghi V, Veiras LC, Tomat A, Munoz MC, Cao G, et al. (2012). Angiotensin-(1-7) attenuates diabetic nephropathy in Zucker diabetic fatty rats. Am J Physiol Renal Physiol 302: F1606-F1615.
50. Goodwin A, Jenkins G, (2009). Role of integrin-mediated TGFbeta activation in the pathogenesis of pulmonary fibrosis. Biochem Soc Trans 37 (Pt 4): 849-854.
51. Gray MO, Long CS, Kalinyak JE, Li HT, Karliner JS, (1998). Angiotensin II stimulates cardiac myocyte hypertrophy via paracrine release of TGF-beta 1 and endothelin-1 from fibroblasts. Cardiovasc Res 40: 352-363.
52. Grobe JL, Mecca AP, Lingis M, Shenoy V, Bolton TA, Machado JM, et al. (2007). Prevention of angiotensin II-induced cardiac remodeling by angiotensin-(1-7). Am J Physiol Heart Circ Physiol 292: H736-H742.
53. Guo YJ, Li WH, Wu R, Xie Q, Cui LQ, (2008). ACE2 overexpression inhibits angiotensin II-induced monocyte chemoattractant protein-1 expression in macrophages. Arch Med Res 39: 149-154.
54. Guyton AC, (1992). Kidneys and fluids in pressure regulation. Small volume but large pressure changes. Hypertension 19 (1 Suppl.): I2-I8.
55. Hall JE, Guyton AC, Mizelle HL, (1990). Role of the renin-angiotensin system in control of sodium excretion and arterial pressure. Acta Physiol Scand Suppl 591: 48-62.
56. Handa RK, (1999). Angiotensin-(1-7) can interact with the rat proximal tubule AT(4) receptor system. Am J Physiol 277 (1 Pt 2): F75-F83.
57. Hernandez Prada JA, Ferreira AJ, Katovich MJ, Shenoy V, Qi Y, Santos RA, et al. (2008). Structure-based identification of small-molecule angiotensin-converting enzyme 2 activators as novel antihypertensive agents. Hypertension 51: 1312-1317.
58. Huentelman MJ, Grobe JL, Vazquez J, Stewart JM, Mecca AP, Katovich MJ, et al. (2005). Protection from angiotensin II-induced cardiac hypertrophy and fibrosis by systemic lentiviral delivery of ACE2 in rats. Exp Physiol 90: 783-790.
59. Inagami T, (1998). A memorial to Robert Tiegerstedt: the centennial of renin discovery. Hypertension 32: 953-957.
60. Iwata M, Cowling RT, Gurantz D, Moore C, Zhang S, Yuan JX, et al. (2005). Angiotensin-(1-7) binds to specific receptors on cardiac fibroblasts to initiate antifibrotic and antitrophic effects. Am J Physiol Heart Circ Physiol 289: H2356-H2363.
61. Iyer SN, Chappell MC, Averill DB, Diz DI, Ferrario CM, (1998a). Vasodepressor actions of angiotensin-(1-7) unmasked during combined treatment with lisinopril and losartan. Hypertension 31: 699-705.
62. Iyer SN, Ferrario CM, Chappell MC, (1998b). Angiotensin-(1-7) contributes to the antihypertensive effects of blockade of the renin-angiotensin system. Hypertension 31 (1 Pt 2): 356-361.
63. Ji H, Menini S, Zheng W, Pesce C, Wu X, Sandberg K, (2008). Role of angiotensin-converting enzyme 2 and angiotensin(1-7) in 17beta-oestradiol regulation of renal pathology in renal wrap hypertension in rats. Exp Physiol 93: 648-657.
64. Jiang T, Gao L, Guo J, Lu J, Wang Y, Zhang Y, (2012). Suppressing inflammation by inhibiting NF-kappaB pathway contributes to the neuroprotection of Angiotensin-(1-7) in rats with permanent cerebral ischemia. Br J Pharmacol 167: 1520-1532.
65. Jin HY, Song B, Oudit GY, Davidge ST, Yu HM, Jiang YY, et al. (2012). ACE2 deficiency enhances angiotensin II-mediated aortic profilin-1 expression, inflammation and peroxynitrite production. PLoS ONE 7: e38502.
66. Kassiri Z, Zhong J, Guo D, Basu R, Wang X, Liu PP, et al. (2009). Loss of angiotensin-converting enzyme 2 accelerates maladaptive left ventricular remodeling in response to myocardial infarction. Circ Heart Fail 2: 446-455.
67. Kim S, Iwao H, (2000). Molecular and cellular mechanisms of angiotensin II-mediated cardiovascular and renal diseases. Pharmacol Rev 52: 11-34.
68. Kim S, Ohta K, Hamaguchi A, Yukimura T, Miura K, Iwao H, (1996). Effects of an AT1 receptor antagonist, an ACE inhibitor and a calcium channel antagonist on cardiac gene expressions in hypertensive rats. Br J Pharmacol 118: 549-556.
69. Kocks MJ, Lely AT, Boomsma F, de Jong PE, Navis G, (2005). Sodium status and angiotensin-converting enzyme inhibition: effects on plasma angiotensin-(1-7) in healthy man. J Hypertens 23: 597-602.
70. Kokubu T, Ueda E, Joh T, Nishimura K, (1979). Purification and properties of angiotensin I-converting enzyme in human lung and its role on the metabolism of vasoactive peptides in pulmonary circulation. Adv Exp Med Biol 120B: 467-475.
71. Kon V, Linton MF, Fazio S, (2011). Atherosclerosis in chronic kidney disease: the role of macrophages. Nat Rev Nephrol 7: 45-54.
72. Kostenis E, Milligan G, Christopoulos A, Sanchez-Ferrer CF, Heringer-Walther S, Sexton PM, et al. (2005). G-protein-coupled receptor Mas is a physiological antagonist of the angiotensin II type 1 receptor. Circulation 111: 1806-1813.
73. Kuba K, Imai Y, Penninger JM, (2006). Angiotensin-converting enzyme 2 in lung diseases. Curr Opin Pharmacol 6: 271-276.
74. Lara Lda S, Cavalcante F, Axelband F, De Souza AM, Lopes AG, Caruso-Neves C, (2006). Involvement of the Gi/o/cGMP/PKG pathway in the AT2-mediated inhibition of outer cortex proximal tubule Na+-ATPase by Ang-(1-7). Biochem J 395: 183-190.
75. Li X, Molina-Molina M, Abdul-Hafez A, Uhal V, Xaubet A, Uhal BD, (2008). Angiotensin converting enzyme-2 is protective but downregulated in human and experimental lung fibrosis. Am J Physiol Lung Cell Mol Physiol 295: L178-L185.
76. Li Y, Wu J, He Q, Shou Z, Zhang P, Pen W, et al. (2009). Angiotensin (1-7) prevent heart dysfunction and left ventricular remodeling caused by renal dysfunction in 5/6 nephrectomy mice. Hypertens Res 32: 369-374.
77. Libby P, (2009). Molecular and cellular mechanisms of the thrombotic complications of atherosclerosis. J Lipid Res 50 (Suppl.): S352-S357.
78. Lindholm LH, Ibsen H, Dahlof B, Devereux RB, Beevers G, de Faire U, et al. (2002). Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 359: 1004-1010.
79. Liu GC, Oudit GY, Fang F, Zhou J, Scholey JW, (2012a). Angiotensin-(1-7)-induced activation of ERK1/2 is cAMP/protein kinase A-dependent in glomerular mesangial cells. Am J Physiol Renal Physiol 302: F784-F790.
80. Liu J, Ji H, Zheng W, Wu X, Zhu JJ, Arnold AP, et al. (2010). Sex differences in renal angiotensin converting enzyme 2 (ACE2) activity are 17beta-oestradiol-dependent and sex chromosome-independent. Biol Sex Differ 1: 6.
81. Liu Z, Huang XR, Chen HY, Penninger JM, Lan HY, (2012b). Loss of angiotensin-converting enzyme 2 enhances TGF-beta/Smad-mediated renal fibrosis and NF-kappaB-driven renal inflammation in a mouse model of obstructive nephropathy. Lab Invest 92: 650-661.
82. Lo CS, Liu F, Shi Y, Maachi H, Chenier I, Godin N, et al. (2012). Dual RAS blockade normalizes angiotensin-converting enzyme-2 expression and prevents hypertension and tubular apoptosis in Akita angiotensinogen-transgenic mice. Am J Physiol Renal Physiol 302: F840-F852.
83. Lopez Ordieres MG, Gironacci M, Rodriguez de Lores Arnaiz G, Pena C, (1998). Effect of angiotensin-(1-7) on ATPase activities in several tissues. Regul Pept 77: 135-139.
84. Lubel JS, Herath CB, Tchongue J, Grace J, Jia Z, Spencer K, et al. (2009). Angiotensin-(1-7), an alternative metabolite of the renin-angiotensin system, is up-regulated in human liver disease and has antifibrotic activity in the bile-duct-ligated rat. Clin Sci (Lond) 117: 375-386.
85. Luque M, Martin P, Martell N, Fernandez C, Brosnihan KB, Ferrario CM, (1996). Effects of captopril related to increased levels of prostacyclin and angiotensin-(1-7) in essential hypertension. J Hypertens 14: 799-805.
86. McCollum LT, Gallagher PE, Ann Tallant E, (2012). Angiotensin-(1-7) attenuates angiotensin II-induced cardiac remodeling associated with upregulation of dual-specificity phosphatase 1. Am J Physiol Heart Circ Physiol 302: H801-H810.
87. Ma TK, Kam KK, Yan BP, Lam YY, (2010). Renin-angiotensin-aldosterone system blockade for cardiovascular diseases: current status. Br J Pharmacol 160: 1273-1292.
88. Magaldi AJ, Cesar KR, de Araujo M, Simoes e Silva AC, Santos RA, (2003). Angiotensin-(1-7) stimulates water transport in rat inner medullary collecting duct: evidence for involvement of vasopressin V2 receptors. Pflugers Arch 447: 223-230.
89. Marques FD, Melo MB, Souza LE, Irigoyen MC, Sinisterra RD, de Sousa FB, et al. (2012). Beneficial effects of long-term administration of an oral formulation of Angiotensin-(1-7) in infarcted rats. Int J Hypertens 2012: 795452.
90. Mateo T, Abu Nabah YN, Abu Taha M, Mata M, Cerda-Nicolas M, Proudfoot AE, et al. (2006). Angiotensin II-induced mononuclear leukocyte interactions with arteriolar and venular endothelium are mediated by the release of different CC chemokines. J Immunol 176: 5577-5586.
91. Mehta PK, Griendling KK, (2007). Angiotensin II cell signaling: physiological and pathological effects in the cardiovascular system. Am J Physiol Cell Physiol 292: C82-C97.
92. Menezes GB, Mansur DS, McDonald B, Kubes P, Teixeira MM, (2011). Sensing sterile injury: opportunities for pharmacological control. Pharmacol Ther 132: 204-214.
93. Mercure C, Yogi A, Callera GE, Aranha AB, Bader M, Ferreira AJ, et al. (2008). Angiotensin(1-7) blunts hypertensive cardiac remodeling by a direct effect on the heart. Circ Res 103: 1319-1326.
94. Mizuiri S, Hemmi H, Arita M, Aoki T, Ohashi Y, Miyagi M, et al. (2011). Increased ACE and decreased ACE2 expression in kidneys from patients with IgA nephropathy. Nephron Clin Pract 117: c57-c66.
95. Moon JY, Tanimoto M, Gohda T, Hagiwara S, Yamazaki T, Ohara I, et al. (2011). Attenuating effect of angiotensin-(1-7) on angiotensin II-mediated NAD(P)H oxidase activation in type 2 diabetic nephropathy of KK-A(y)/Ta mice. Am J Physiol Renal Physiol 300: F1271-F1282.
96. Nabah YN, Mateo T, Estelles R, Mata M, Zagorski J, Sarau H, et al. (2004). Angiotensin II induces neutrophil accumulation in vivo through generation and release of CXC chemokines. Circulation 110: 3581-3586.
97. Nabah AYN, Losada M, Estelles R, Mateo T, Company C, Piqueras L, et al. (2007). CXCR2 blockade impairs angiotensin II-induced CC chemokine synthesis and mononuclear leukocyte infiltration. Arterioscler Thromb Vasc Biol 27: 2370-2376.
98. Nadu AP, Ferreira AJ, Reudelhuber TL, Bader M, Santos RA, (2008). Reduced isoproterenol-induced renin-angiotensin changes and extracellular matrix deposition in hearts of TGR(A1-7)3292 rats. J Am Soc Hypertens 2: 341-348.
99. Nakamura K, Koibuchi N, Nishimatsu H, Higashikuni Y, Hirata Y, Kugiyama K, et al. (2008). Candesartan ameliorates cardiac dysfunction observed in angiotensin-converting enzyme 2-deficient mice. Hypertens Res 31: 1953-1961.
100. Nogueira AI, Souza Santos RA, Simoes e Silva AC, Cabral AC, Vieira RL, Drumond TC, et al. (2007). The pregnancy-induced increase of plasma angiotensin-(1-7) is blunted in gestational diabetes. Regul Pept 141: 55-60.
101. Oudit GY, Herzenberg AM, Kassiri Z, Wong D, Reich H, Khokha R, et al. (2006). Loss of angiotensin-converting enzyme-2 leads to the late development of angiotensin II-dependent glomerulosclerosis. Am J Pathol 168: 1808-1820.
102. Oudit GY, Kassiri Z, Patel MP, Chappell M, Butany J, Backx PH, et al. (2007). Angiotensin II-mediated oxidative stress and inflammation mediate the age-dependent cardiomyopathy in ACE2 null mice. Cardiovasc Res 75: 29-39.
103. Oudit GY, Liu GC, Zhong J, Basu R, Chow FL, Zhou J, et al. (2010). Human recombinant ACE2 reduces the progression of diabetic nephropathy. Diabetes 59: 529-538.
104. Owen CA, Campbell EJ, (1998). Angiotensin II generation at the cell surface of activated neutrophils: novel cathepsin G-mediated catalytic activity that is resistant to inhibition. J Immunol 160: 1436-1443.
105. Pereira RM, Santos RA, Teixeira MM, Leite VH, Costa LP, da Costa Dias FL, et al. (2007). The renin-angiotensin system in a rat model of hepatic fibrosis: evidence for a protective role of Angiotensin-(1-7). J Hepatol 46: 674-681.
106. Petri B, Phillipson M, Kubes P, (2008). The physiology of leukocyte recruitment: an in vivo perspective. J Immunol 180: 6439-6446.
107. Pinheiro SV, Simoes e Silva AC, Sampaio WO, de Paula RD, Mendes EP, Bontempo ED, et al. (2004). Nonpeptide AVE 0991 is an angiotensin-(1-7) receptor Mas agonist in the mouse kidney. Hypertension 44: 490-496.
108. Pinheiro SV, Ferreira AJ, Kitten GT, da Silveira KD, da Silva DA, Santos SH, et al. (2009). Genetic deletion of the angiotensin-(1-7) receptor Mas leads to glomerular hyperfiltration and microalbuminuria. Kidney Int 75: 1184-1193.
109. Piqueras L, Kubes P, Alvarez A, O'Connor E, Issekutz AC, Esplugues JV, et al. (2000). Angiotensin II induces leukocyte-endothelial cell interactions in vivo via AT(1) and AT(2) receptor-mediated P-selectin upregulation. Circulation 102: 2118-2123.
110. Powers B, Greene L, Balfe LM, (2011). Updates on the treatment of essential hypertension: a summary of AHRQ's comparative effectiveness review of angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, and direct renin inhibitors. J Manag Care Pharm 17 (8 Suppl.): S1-S14.
111. Ren Y, Garvin JL, Carretero OA, (2002). Vasodilator action of angiotensin-(1-7) on isolated rabbit afferent arterioles. Hypertension 39: 799-802.
112. Rosenkranz S, (2004). TGF-beta1 and angiotensin networking in cardiac remodeling. Cardiovasc Res 63: 423-432.
113. Ruiz-Ortega M, Lorenzo O, Suzuki Y, Ruperez M, Egido J, (2001). Proinflammatory actions of angiotensins. Curr Opin Nephrol Hypertens 10: 321-329.
114. Ruiz-Ortega M, Ruperez M, Esteban V, Rodriguez-Vita J, Sanchez-Lopez E, Carvajal G, et al. (2006). Angiotensin II: a key factor in the inflammatory and fibrotic response in kidney diseases. Nephrol Dial Transplant 21: 16-20.
115. Sadoshima J, Izumo S, (1993). Molecular characterization of angiotensin II-induced hypertrophy of cardiac myocytes and hyperplasia of cardiac fibroblasts. Critical role of the AT1 receptor subtype. Circ Res 73: 413-423.
116. Sampaio WO, Nascimento AA, Santos RA, (2003). Systemic and regional hemodynamic effects of angiotensin-(1-7) in rats. Am J Physiol Heart Circ Physiol 284: H1985-H1994.
117. Sampaio WO, Henrique de Castro C, Santos RA, Schiffrin EL, Touyz RM, (2007). Angiotensin-(1-7) counterregulates angiotensin II signaling in human endothelial cells. Hypertension 50: 1093-1098.
118. Santiago NM, Guimaraes PS, Sirvente RA, Oliveira LA, Irigoyen MC, Santos RA, et al. (2010). Lifetime overproduction of circulating Angiotensin-(1-7) attenuates deoxycorticosterone acetate-salt hypertension-induced cardiac dysfunction and remodeling. Hypertension 55: 889-896.
119. Santos RA, Baracho NC, (1992). Angiotensin-(1-7) is a potent antidiuretic peptide in rats. Braz J Med Biol Res 25: 651-654.
120. Santos RA, Campagnole-Santos MJ, Baracho NC, Fontes MA, Silva LC, Neves LA, et al. (1994). Characterization of a new angiotensin antagonist selective for angiotensin-(1-7): evidence that the actions of angiotensin-(1-7) are mediated by specific angiotensin receptors. Brain Res Bull 35: 293-298.
121. Santos RA, Simoes e Silva AC, Magaldi AJ, Khosla MC, Cesar KR, Passaglio KT, et al. (1996). Evidence for a physiological role of angiotensin-(1-7) in the control of hydroelectrolyte balance. Hypertension 27: 875-884.
122. Santos RA, Passaglio KT, Pesquero JB, Bader M, Simoes e Silva AC, (2001). Interactions between angiotensin-(1-7), kinins, and angiotensin II in kidney and blood vessels. Hypertension 38 (3 Pt 2): 660-664.
123. Santos RA, Haibara AS, Campagnole-Santos MJ, Simoes e Silva AC, Paula RD, Pinheiro SV, et al. (2003a). Characterization of a new selective antagonist for angiotensin-(1-7), d-pro7-angiotensin-(1-7). Hypertension 41 (3 Pt 2): 737-743.
124. Santos RA, Simoes e Silva AC, Maric C, Silva DM, Machado RP, de Buhr I, et al. (2003b). Angiotensin-(1-7) is an endogenous ligand for the G protein-coupled receptor Mas. Proc Natl Acad Sci U S A 100: 8258-8263.
125. Santos RA, Ferreira AJ, Nadu AP, Braga AN, de Almeida AP, Campagnole-Santos MJ, et al. (2004). Expression of an angiotensin-(1-7)- producing fusion protein produces cardioprotective effects in rats. Physiol Genomics 17: 292-299.
126. Santos RA, Castro CH, Gava E, Pinheiro SV, Almeida AP, Paula RD, et al. (2006). Impairment of in vitro and in vivo heart function in angiotensin-(1-7) receptor MAS knockout mice. Hypertension 47: 996-1002.
127. Sanz MJ, Kubes P, (2012). Neutrophil-active chemokines in in vivo imaging of neutrophil trafficking. Eur J Immunol 42: 278-283.
128. Schiavone MT, Santos RA, Brosnihan KB, Khosla MC, Ferrario CM, (1988). Release of vasopressin from the rat hypothalamo-neurohypophysial system by angiotensin-(1-7) heptapeptide. Proc Natl Acad Sci U S A 85: 4095-4098.
129. Schmieder RE, Ruilope LM, Barnett AH, (2011). Renal protection with angiotensin receptor blockers: where do we stand. J Nephrol 24: 569-580.
130. Shah A, Oh YB, Lee SH, Lim JM, Kim SH, (2012). Angiotensin-(1-7) attenuates hypertension in exercise-trained renal hypertensive rats. Am J Physiol Heart Circ Physiol 302: H2372-H2380.
131. Shenoy V, Grobe JL, Qi Y, Ferreira AJ, Fraga-Silva RA, Collamat G, et al. (2009). 17beta-Estradiol modulates local cardiac renin-angiotensin system to prevent cardiac remodeling in the DOCA-salt model of hypertension in rats. Peptides 30: 2309-2315.
132. Shenoy V, Ferreira AJ, Qi Y, Fraga-Silva RA, Diez-Freire C, Dooies A, et al. (2010). The angiotensin-converting enzyme 2/angiogenesis-(1-7)/Mas axis confers cardiopulmonary protection against lung fibrosis and pulmonary hypertension. Am J Respir Crit Care Med 182: 1065-1072.
133. Silveira KD, Coelho FM, Vieira AT, Sachs D, Barroso LC, Costa VV, et al. (2010a). Anti-inflammatory effects of the activation of the angiotensin-(1-7) receptor, MAS, in experimental models of arthritis. J Immunol 185: 5569-5576.
134. Silveira KD, Pompermayer Bosco KS, Diniz LR, Carmona AK, Cassali GD, Bruna-Romero O, et al. (2010b). ACE2-angiotensin-(1-7)-Mas axis in renal ischaemia/reperfusion injury in rats. Clin Sci (Lond) 119: 385-394.
135. Silveira KD, Santos RA, Barroso LC, Lima CX, Teixeira MM, Simoes Silva AC, (2010c). The administration of the agonist of angiotensin-(1-7), AVE0991, improved inflammation and proteinuria in experimental nephrotic syndrome. In:15th Congress of the International Pediatric Nephrology Association. Pediatr Nephrol 25: 1795.
136. Simoes e Silva AC, Flynn JT, (2012). The renin-angiotensin-aldosterone system in 2011: role in hypertension and chronic kidney disease. Pediatr Nephrol 10: 1835-1845.
137. Simoes e Silva AC, Baracho NC, Passaglio KT, Santos RA, (1997). Renal actions of angiotensin-(1-7). Braz J Med Biol Res 30: 503-513.
138. Simoes e Silva AC, Bello AP, Baracho NC, Khosla MC, Santos RA, (1998). Diuresis and natriuresis produced by long term administration of a selective Angiotensin-(1-7) antagonist in normotensive and hypertensive rats. Regul Pept 74: 177-184.
139. Simoes e Silva AC, Diniz JS, Regueira Filho A, Santos RA, (2004). The renin angiotensin system in childhood hypertension: selective increase of angiotensin-(1-7) in essential hypertension. J Pediatr 145: 93-98.
140. Simoes e Silva AC, Diniz JS, Pereira RM, Pinheiro SV, Santos RA, (2006). Circulating renin Angiotensin system in childhood chronic renal failure: marked increase of Angiotensin-(1-7) in end-stage renal disease. Pediatr Res 60: 734-739.
141. Soler MJ, Wysocki J, Ye M, Lloveras J, Kanwar Y, Batlle D, (2007). ACE2 inhibition worsens glomerular injury in association with increased ACE expression in streptozotocin-induced diabetic mice. Kidney Int 72: 614-623.
142. Souza LL, Costa-Neto CM, (2012). Angiotensin-(1-7) decreases LPS-induced inflammatory response in macrophages. J Cell Physiol 227: 2117-2122.
143. Sriramula S, Cardinale JP, Lazartigues E, Francis J, (2011). ACE2 overexpression in the paraventricular nucleus attenuates angiotensin II-induced hypertension. Cardiovasc Res 92: 401-408.
144. Stegbauer J, Oberhauser V, Vonend O, Rump LC, (2004). Angiotensin-(1-7) modulates vascular resistance and sympathetic neurotransmission in kidneys of spontaneously hypertensive rats. Cardiovasc Res 61: 352-359.
145. Su Z, Zimpelmann J, Burns KD, (2006). Angiotensin-(1-7) inhibits angiotensin II-stimulated phosphorylation of MAP kinases in proximal tubular cells. Kidney Int 69: 2212-2218.
146. Sukumaran V, Veeraveedu PT, Gurusamy N, Yamaguchi K, Lakshmanan AP, Ma M, et al. (2011). Cardioprotective effects of telmisartan against heart failure in rats induced by experimental autoimmune myocarditis through the modulation of angiotensin-converting enzyme-2/angiotensin 1-7/mas receptor axis. Int J Biol Sci 7: 1077-1092.
147. Sukumaran V, Veeraveedu PT, Gurusamy N, Lakshmanan AP, Yamaguchi K, Ma M, et al. (2012). Telmisartan acts through the modulation of ACE-2/ANG 1-7/mas receptor in rats with dilated cardiomyopathy induced by experimental autoimmune myocarditis. Life Sci 90: 289-300.
148. Sun Y, Zhang JQ, Zhang J, Ramires FJ, (1998). Angiotensin II, transforming growth factor-beta1 and repair in the infarcted heart. J Mol Cell Cardiol 30: 1559-1569.
149. Suzuki Y, Ruiz-Ortega M, Lorenzo O, Ruperez M, Esteban V, Egido J, (2003). Inflammation and angiotensin II. Int J Biochem Cell Biol 35: 881-900.
150. Tallant EA, Clark MA, (2003). Molecular mechanisms of inhibition of vascular growth by angiotensin-(1-7). Hypertension 42: 574-579.
151. Tallant EA, Ferrario CM, Gallagher PE, (2005). Angiotensin-(1-7) inhibits growth of cardiac myocytes through activation of the mas receptor. Am J Physiol Heart Circ Physiol 289: H1560-H1566.
152. Thomas MC, Pickering RJ, Tsorotes D, Koitka A, Sheehy K, Bernardi S, et al. (2010). Genetic Ace2 deficiency accentuates vascular inflammation and atherosclerosis in the ApoE knockout mouse. Circ Res 107: 888-897.
153. Thomas MC, Jandeleit-Dahm KA, Tikellis C, (2012). The renoprotective actions of peroxisome proliferator-activated receptors agonists in diabetes. PPAR Res 2012: 456529.
154. Tipnis SR, Hooper NM, Hyde R, Karran E, Christie G, Turner AJ, (2000). A human homolog of angiotensin-converting enzyme. Cloning and functional expression as a captopril-insensitive carboxypeptidase. J Biol Chem 275: 33238-33243.
155. Tocci G, Volpe M, (2011). End-organ protection in patients with hypertension: focus on the role of angiotensin receptor blockers on renal function. Drugs 71: 1003-1017.
156. Touyz RM, Berry C, (2002). Recent advances in angiotensin II signaling. Braz J Med Biol Res 35: 1001-1015.
157. le Tran Y, Forster C, (1997). Angiotensin-(1-7) and the rat aorta: modulation by the endothelium. J Cardiovasc Pharmacol 30: 676-682.
158. Uhal BD, Li X, Piasecki CC, Molina-Molina M, (2012). Angiotensin signalling in pulmonary fibrosis. Int J Biochem Cell Biol 44: 465-468.
159. Vallon V, Richter K, Heyne N, Osswald H, (1997). Effect of intratubular application of angiotensin 1-7 on nephron function. Kidney Blood Press Res 20: 233-239.
160. Velkoska E, Dean RG, Griggs K, Burchill L, Burrell LM, (2011). Angiotensin-(1-7) infusion is associated with increased blood pressure and adverse cardiac remodelling in rats with subtotal nephrectomy. Clin Sci (Lond) 120: 335-345.
161. Vickers C, Hales P, Kaushik V, Dick L, Gavin J, Tang J, et al. (2002). Hydrolysis of biological peptides by human angiotensin-converting enzyme-related carboxypeptidase. J Biol Chem 277: 14838-14843.
162. Vilas-Boas WW, Ribeiro-Oliveira A Jr, Pereira RM, Ribeiro Rda C, Almeida J, Nadu AP, et al. (2009). Relationship between angiotensin-(1-7) and angiotensin II correlates with hemodynamic changes in human liver cirrhosis. World J Gastroenterol 15: 2512-2519.
163. Weir MR, (2007). Effects of renin-angiotensin system inhibition on end-organ protection: can we do better? Clin Ther 29: 1803-1824.
164. Wiemer G, Dobrucki LW, Louka FR, Malinski T, Heitsch H, (2002). AVE 0991, a nonpeptide mimic of the effects of angiotensin-(1-7) on the endothelium. Hypertension 40: 847-852.
165. Williams MR, Azcutia V, Newton G, Alcaide P, Luscinskas FW, (2011). Emerging mechanisms of neutrophil recruitment across endothelium. Trends Immunol 32: 461-469.
166. Wong DW, Oudit GY, Reich H, Kassiri Z, Zhou J, Liu QC, et al. (2007). Loss of angiotensin-converting enzyme-2 (Ace2) accelerates diabetic kidney injury. Am J Pathol 171: 438-451.
167. Wysocki J, Ye M, Soler MJ, Gurley SB, Xiao HD, Bernstein KE, et al. (2006). ACE and ACE2 activity in diabetic mice. Diabetes 55: 2132-2139.
168. Xue H, Zhou L, Yuan P, Wang Z, Ni J, Yao T, et al. (2012). Counteraction between angiotensin II and angiotensin-(1-7) via activating angiotensin type I and Mas receptor on rat renal mesangial cells. Regul Pept 177: 12-20.
169. Yamamoto K, Ohishi M, Katsuya T, Ito N, Ikushima M, Kaibe M, et al. (2006). Deletion of angiotensin-converting enzyme 2 accelerates pressure overload-induced cardiac dysfunction by increasing local angiotensin II. Hypertension 47: 718-726.
170. Yamazato Y, Ferreira AJ, Hong KH, Sriramula S, Francis J, Yamazato M, et al. (2009). Prevention of pulmonary hypertension by Angiotensin-converting enzyme 2 gene transfer. Hypertension 54: 365-371.
171. Ye M, Wysocki J, William J, Soler MJ, Cokic I, Batlle D, (2006). Glomerular localization and expression of Angiotensin-converting enzyme 2 and Angiotensin-converting enzyme: implications for albuminuria in diabetes. J Am Soc Nephrol 17: 3067-3075.
172. Yu CM, Tipoe GL, Wing-Hon Lai K, Lau CP, (2001). Effects of combination of angiotensin-converting enzyme inhibitor and angiotensin receptor antagonist on inflammatory cellular infiltration and myocardial interstitial fibrosis after acute myocardial infarction. J Am Coll Cardiol 38: 1207-1215.
173. Zeng W, Chen W, Leng X, He JG, Ma H, (2009). Chronic angiotensin-(1-7) administration improves vascular remodeling after angioplasty through the regulation of the TGF-beta/Smad signaling pathway in rabbits. Biochem Biophys Res Commun 389: 138-144.
174. Zhang J, Noble NA, Border WA, Huang Y, (2010). Infusion of angiotensin-(1-7) reduces glomerulosclerosis through counteracting angiotensin II in experimental glomerulonephritis. Am J Physiol Renal Physiol 298: F579-F588.
175. Zhong J, Basu R, Guo D, Chow FL, Byrns S, Schuster M, et al. (2010). Angiotensin-converting enzyme 2 suppresses pathological hypertrophy, myocardial fibrosis, and cardiac dysfunction. Circulation 122: 717-728. 718 p following 728.
176. Zimmerman D, Burns KD, (2012). Angiotensin-(1-7) in kidney disease: a review of the controversies. Clin Sci (Lond) 123: 333-346.
177. Zimpelmann J, Burns KD, (2009). Angiotensin-(1-7) activates growth-stimulatory pathways in human mesangial cells. Am J Physiol Renal Physiol 296: F337-F346.